Search

Your search keyword '"enfermedad Coronavirus 2019"' showing total 3 results
Start Over Descriptor "enfermedad Coronavirus 2019"
3 results on '"enfermedad Coronavirus 2019"'

1. Vitamina D a la admisión y severidad de la enfermedad en pacientes con COVID-19 en la Unidad de Cuidados Intensivos

Author

Victoria Gonzalez, Cayetano Galletti, Romina Alvarez Vizzoni, Yanina Saldivar, Nicolás Kessler, Francisco Irades, Estefanía Minoldo, Pablo Calcagno, Antonella Aliscioni, and Ursula Zaya

Subjects
enfermedad Coronavirus 2019, Vitamina D, ventilación mecánica, unidad de cuidados intensivos, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Introducción: La 25-hidroxivitamina D (25(OH)D) disminuiría la incidencia de infecciones respiratorias virales, por su efecto pleiotrópico en la inmunomodulación. Objetivo: evaluamos la influencia de la deficiencia severa de 25(OH)D con la severidad de la enfermedad COVID-19. Métodos: estudio retrospectivo observacional, que incluyó 164 pacientes con diagnóstico de COVID-19 ingresados a la unidad de cuidados intensivos que tuvieran valores plasmáticos de 25(OH)D las primeras 72 horas de internación. Resultados: exhibieron deficiencia de 25(OH)D (

Published
2023

2. The effects of renin-angiotensin system inhibitors (RASI) in Corona Virus Disease (COVID-19) with Hypertension: A retrospective, single-center trial

Author

Xin Cheng, Zhenyu Fan, Haiming Cui, Min Fan, Feng Wu, and Jilin Cheng

Subjects
Adult, Male, China, medicine.medical_specialty, Pneumonia, Viral, Angiotensin-Converting Enzyme Inhibitors, Disease, medicine.disease_cause, Single Center, Severity of Illness Index, Enfermedad Coronavirus 2019, Article, Betacoronavirus, Renin–angiotensin system inhibitors, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Renin-inhibidores del sistema de angiotensina, Hipertensión, Severity of illness, medicine, Humans, 030212 general & internal medicine, Pandemics, Aged, Retrospective Studies, Coronavirus, Aged, 80 and over, Coronavirus disease 2019, SARS-CoV-2, business.industry, Brief Report, Case-control study, COVID-19, Retrospective cohort study, renin-angiotensin system inhibitors, General Medicine, Middle Aged, Prognosis, Entry into host, Blood pressure, Cough, Case-Control Studies, Hypertension, Female, Coronavirus Infections, business
Abstract

Introduction and objective A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin–angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with hypertension. Patients and method In this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI. Results Comparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated. Conclusions Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms.

Published
2020

3. The effects of renin-angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial.

Author

Cui H, Wu F, Fan Z, Cheng X, Cheng J, and Fan M

Subjects
Adult, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors therapeutic use, COVID-19, Case-Control Studies, China, Coronavirus Infections diagnosis, Coronavirus Infections therapy, Cough chemically induced, Cough virology, Female, Humans, Hypertension complications, Male, Middle Aged, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral therapy, Prognosis, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Angiotensin-Converting Enzyme Inhibitors adverse effects, Betacoronavirus, Coronavirus Infections etiology, Hypertension drug therapy, Pneumonia, Viral etiology
Abstract

Introduction and Objective: A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin-angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with hypertension., Patients and Method: In this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI., Results: Comparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated., Conclusions: Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms., (Copyright © 2020 The Authors. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results